Unlike some other manufacturers, Samsung Biologics has enjoyed a revenue boost from the novel coronavirus pandemic, and it’s accelerating its expansion plans to match. With a $2 billion “super plant” in the offing, Samsung now has a new Big Pharma supply deal in place to keep driving growth.
AstraZeneca tapped Samsung Biologics for a $331 million supply pact to produce bulk drug substance and “drug product to support AstraZeneca’s biologics therapeutics” at the CMO’s Plant 3 facility in Incheon, South Korea, the partners said Tuesday.
Image: Samsung Biologics’ expansion plans include a $2 billion “super plant” at the CMO’s Incheon complex. (Samsung)
{iframe}https://www.fiercepharma.com/manufacturing/astrazeneca-samsung-reach-331m-supply-deal-for-biologics-manufacturing{/iframe}